<?xml version="1.0" encoding="utf-8"?> 

<rss version="2.0"> 

<channel>

<title>LexisNexis&#174; Mealey's&#8482; Diabetes Drugs Legal News</title>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

<description>Headline Diabetes Drugs Legal News from LexisNexis&#174;</description>

<language>en-us</language>

<image>

<title>LexisNexis&#174; Headline Diabetes Drugs Legal News</title>

<url>http://www.lexisnexis.com/mealeys/images/lexismealeyslogo.gif</url>

<width>130</width> 
  
<height>29</height>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

</image> 

<copyright>Copyright 2009</copyright>

<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia Plaintiff Disputes GSK's Headquarters Is In Philadelphia</title>
<description>
<![CDATA[PHILADELPHIA - An Avandia plaintiff is moving for remand of his case from the multidistrict litigation in the U.S. District Court for the Eastern District of Pennsylvania, arguing that the case should be in the Durham County, N.C., Superior Court because defendant GlaxoSmithKline's corporate headquarters is in that jurisdiction (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 2:07-md-01871-CMR; William B. Brown v. SmithKlineBeecham Corp., d/b/a GlaxoSmithKline, No. 1:08-cv-00885-WO-WWD, M.D. N.C.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Says Claims Against Sales Representative Not Factually Supported</title>
<description>
<![CDATA[PHILADELPHIA - GlaxoSmithKline says in a brief in opposition to remand that a sales representative was fraudulently joined to an Avandia complaint because no viable cause of action was stated against her and because the plaintiff has no real intention to prosecute the action against her (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 2:07-md-01871-CMR; Martinez, et al. v. SmithKline Beecham Corp., et al., No. 2:08-cv-05847-CMR, E.D. Pa.; See January 2009, Page 7). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Stay Reinstated For Plaintiff To Oppose MDL Transfer</title>
<description>
<![CDATA[WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation on Jan. 21 reinstated the stay of a conditional transfer order for Harout Ohannessian's Avandia case to the Avandia MDL, stating that although records show that the transfer order was sent to the proper address of plaintiff's counsel, the plaintiff's assertion that he did not receive the order justifies reinstatement so that he may pursue an opposition to transfer (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 2:07-md-01871-CMR, E.D. Pa.; Harout Ohannessian, et al. v. SmithKline Beecham Corp., et al., No. 2:08-8151, C.D. Calif.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Redgrave Appointed Electronic Discovery Master</title>
<description>
<![CDATA[PHILADELPHIA - The Avandia multidistrict litigation judge on Jan. 29 issued an order appointing Jonathan Redgrave as electronic discovery master (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia MDL Status Conference Scheduled For Feb. 27</title>
<description>
<![CDATA[PHILADELPHIA - The Avandia multidistrict litigation judge on Jan. 22 issued an order setting the next status conference for Feb. 27 (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3 California Cases Transferred to Avandia MDL</title>
<description>
<![CDATA[PHILADELPHIA - The Judicial Panel on Multidistrict Litigation (JPMDL) on Feb. 4 issued an order transferring three additional California cases to the Avandia MDL in the U.S. District Court for the Eastern District of Pennsylvania for pretrial proceedings (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Wyeth: Pfizer Deal Merits No Change In Corporate Disclosure In Levine Drug Preemption Case</title>
<description>
<![CDATA[WASHINGTON, D.C. - Wyeth on Feb. 4 told the U.S. Supreme Court about Pfizer Inc.'s plans to buy Wyeth but said that warrants no change in its corporate disclosure statement filed in the Wyeth v. Diana Levine drug preemption case pending before the court (Wyeth v. Diana Levine, No. 06-1249, U.S. Sup.; See November 2008, Page 5). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Reports 49 Percent Decline In 2008 U.S. Avandia Sales</title>
<description>
<![CDATA[LONDON - GlaxoSmithKline (GSK) announced that sales of Avandia products dropped 40 percent worldwide and 49 percent in the United States during 2008. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Reserves $400M For Drug Marketing Probe</title>
<description>
<![CDATA[PHILADELPHIA - GlaxoSmithKline plc (GSK) said Jan. 29 that it will take a $400 million charge against earnings relating to an ongoing investigation into its marketing of several drugs between 1997 and 2004. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-4 Mealeys Diabetes Drug Report 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GAO: FDA Is 'At High Risk' For Guaranteeing Safety</title>
<description>
<![CDATA[WASHINGTON, D.C. - The Food and Drug Administration's oversight of medical products has been added to a list of federal programs that are "at high risk," the Government Accountability Office (GAO) says in a Jan. 22 report. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-4 Mealey's Diabetes Drug Report 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Says 6 Plaintiffs' Avandia Did Not Come From McKesson</title>
<description>
<![CDATA[PHILADELPHIA - In a Dec. 10 supplemental submission in opposition to remand, SmithKline Beecham Corp., d/b/a GlaxoSmithKline (GSK), identified six California plaintiffs whose Avandia prescriptions could not have been distributed by McKesson Corp. (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-MD-1871, E.D. Pa.; See August 2008, Page 4). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Says Decision To Close Headquarters Irrelevant To Remand Motion</title>
<description>
<![CDATA[PHILADELPHIA - Judge Cynthia Rufe of the Avandia multidistrict litigation on Dec. 15 approved a motion by defendant SmithKline Beecham (doing business as GlaxoSmithKline [GSK]) to file a surreply in opposition to a plaintiff's reply brief, in which it argues that its November announcement that its U.S. pharmaceutical headquarters would be based in North Carolina is irrelevant to the plaintiff's motion to remand because it occurred months after the motion was filed (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871; Mary Massey v. GlaxoSmithKline USA, et al., No. 2:08-cv-04981-CMR, E.D. Pa.; See December 2008, Page 8). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Says FDA Approval Of Labeling Prevents Remand</title>
<description>
<![CDATA[PHILADELPHIA - SmithKline Beecham, d/b/a GlaxoSmithKline (GSK), argues in a Jan. 6 brief that an Avandia multidistrict litigation plaintiff has fraudulently joined Rite Aid Pharmacy in order to avoid diversity jurisdiction (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-MD-1871, E.D. Pa.; John Scardino, Jr. v. SmithKlineBeecham Corp., et al., No. 2:08-cv-05823-CMR, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>New Mexico Plaintiffs Argue Sales Rep Properly Joined</title>
<description>
<![CDATA[PHILADELPHIA - The plaintiffs in a case pending before the Avandia multidistrict litigation are arguing that federal jurisdiction is lacking because they have properly joined an in-state pharmaceutical sales representative and that the case should be remanded to state court (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 2:07-md-01871-CMR). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Protocol For Withdrawal Of Counsel Issued In Avandia MDL</title>
<description>
<![CDATA[PHILADELPHIA - The Avandia multidistrict litigation judge recently issued Pretrial Order (PTO) No. 41, which establishes a protocol under which a plaintiffs' attorney may withdraw as counsel and to ensure that the affected plaintiff has adequate representation (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Public Citizen Says Study Should Be 'Last Nail' For Avandia</title>
<description>
<![CDATA[WASHINGTON, D.C. - Dr. Sidney Wolfe, director of the Health Research Group for consumer watchdog Public Citizen, said a recently released study finding a 15 percent higher mortality rate in elderly diabetes patients who took Avandia (rosiglitazone) as compared to those who took Actos (pioglitazone) underscores the dangers of the drug and the need for the product to be taken off the market (See December 2008, Page 11). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Warning Claim For Generics Not Preempted, Judge Rules; Manufacturer Can Change Label</title>
<description>
<![CDATA[BURLINGTON, Vt. - A Vermont federal judge on Dec. 17 ruled that there is no congressional intent to preempt all failure-to-warn litigation by any federal regulation requiring that generic drug labels stay identical to those of predecessor brand-name drugs (Ethel Kellogg v. Wyeth, et al., No. 07-82, D. Vt.; 2008 U.S. Dist. LEXIS 104073). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Sprint Fidelis MDL Claims Ruled Preempted Under Federal Law</title>
<description>
<![CDATA[MINNEAPOLIS - The federal judge in the Medtronic Sprint Fidelis Leads multidistrict litigation on Jan. 5 ruled that all claims in the plaintiffs' master consolidated complaint are preempted by federal law (In Re: Medtronic, Inc. Sprint Fidelis Leads Products Liability Litigation, No. 08-md-1905-RHK-JSM, D. Minn.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-3 Mealeys Diabetes Drug Report 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Kugel MDL Court Declines To Adopt Procedural Misjoinder, Remand Case Directly To State</title>
<description>
<![CDATA[PROVIDENCE, R.I. - The judge overseeing the Kugel patch multidistrict litigation last month declined to adopt the policy of procedural misjoinder and ordered that a case be remanded directly to a California state court (In Re: Kugel Mesh Hernia Patch Litigation, MDL Docket No. 1842, No. 07-1842, Larry Palmer, et al. v. Davol, Inc., et al., No. 08-2499, D. R.I.; 2008 U.S. Dist. LEXIS 103738). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-3 Mealey's Diabetes Drug Report 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>

<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 1%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Wants Multiplaintiff Cases Severed Before Remand Is Decided</title>
<description>
<![CDATA[PHILADELPHIA - GlaxoSmithKline (GSK) is arguing that the Avandia multidistrict litigation judge should sever the joined claims of unrelated plaintiffs in a number of pending motions to remand and consider the jurisdiction of each case individually (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.; See related story in this issue). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 1 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 2%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia Plaintiffs Submit Remand Motion Classifications</title>
<description>
<![CDATA[PHILADELPHIA - Pursuant to Pretrial Order No. 40 in the Avandia multidistrict litigation, the Plaintiffs' Steering Committee filed its suggestions for categorization of the cases subject to motions to remand pending before the court (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.; See related story in this issue). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 2 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 3%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia MDL Judge Will Categorize Remand Motions</title>
<description>
<![CDATA[PHILADELPHIA - The judge in the Avandia multidistrict litigation said in a Nov. 14 pretrial order that she plans to categorize the pending motions to remand before the court based on "significant commonalities in underlying facts, circumstances, claims, parties and jurisdictional features" (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 3 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 4%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Deposition Protocol Established In Avandia MDL</title>
<description>
<![CDATA[PHILADELPHIA - The judge in the Avandia multidistrict litigation on Nov. 11 issued Pretrial Order No. 38, establishing a protocol for depositions of witnesses for the plaintiffs and defense (In Re: Avandia Marketing , Sales Practices and Products Liability Litigation, MDL No. 1871, 07-MD01871-CMR). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 4 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 5%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia Plaintiffs Point To GSK Philadelphia Headquarters Closing In Support of Remand</title>
<description>
<![CDATA[PHILADELPHIA - Two North Carolina Avandia plaintiffs whose motion to remand is pending before the Avandia multidistrict litigation are arguing that defendant GlaxoSmithKline's (GSK) recent decision to close its Philadelphia headquarters, thereby leaving its North Carolina facility as its sole U.S. headquarters, supports their contention that complete diversity does not exist (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871; Mary Massey v. GlaxoSmithKline USA, et al., No. 2:08-cv-04981-CMR, E.D. Pa.; See related story in this issue). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 5 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 6%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK Argues Principal Place Of Business Is In Philadelphia</title>
<description>
<![CDATA[PHILADELPHIA - GlaxoSmithKline (GSK), the defendant in the Avandia multidistrict litigation, is arguing that its principal place of business is in Philadelphia and that, therefore, a motion to remand filed by two North Carolina plaintiffs claiming that the company has its headquarters in their state should be denied (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871; Mary Massey v. GlaxoSmithKline USA, et al., No. 2:08-cv-04981-CMR, E.D. Pa.; See related story in this issue). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 6 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 7%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Plaintiff Alleges Distributor Involved In Avandia Advertising 'Blitz'</title>
<description>
<![CDATA[PHILADELPHIA - An Avandia multidistrict litigation plaintiff argues in her restated motion to remand that local distributor McKesson Corp. took an active role in an advertising blitz to sell the drug to physicians and is therefore not fraudulently joined to her case (Elva Ayala-Castro, et ux, et al. v. GlaxoSmithKline, et al., No. 08-cv-5116; In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, 07-md-01871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 7 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 8%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Doctor Claims SmithKline Stifled Attempts To Express Avandia Concerns</title>
<description>
<![CDATA[HAGERSTOWN, Md. - A Maryland doctor told The Wall Street Journal on Nov. 19 that SmithKline Beecham (d/b/a GlaxoSmithKline, or GSK) attempted to make her stop talking about her concerns about the potentially dangerous side effects of Avandia after the drug came on the market in 1999. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 8 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 9%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Harvard Study Shows 13 Percent Higher Mortality With Avandia</title>
<description>
<![CDATA[CHICAGO - A recently released cohort study found a 15 percent higher mortality rate in elderly diabetes patients who took Avandia (rosliglitazone) as compared to those who took Actos (pioglitazone). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 9 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 10%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia Study Shows No Statistical Decrease In Plaque Buildup</title>
<description>
<![CDATA[NEW ORLEANS - A recently released clinical trial concluded that rosiglitazone (Avandia) did not meet its primary endpoint of statistically reducing the progression of plaque buildup in coronary arteries, as compared with the older drug glipizide (Glucotrol, Glucotrol XL, GlipiZIDE XL). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 10 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%202-2 Mealeys Diabetes Drug Report 11%20(2008)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>GSK's Request For Reconsideration Of Preemption Ruling Denied</title>
<description>
<![CDATA[PHILADELPHIA - A federal judge on Oct. 28 denied a motion by SmithKline Beecham Corp. d/b/a GlaxoSmithKline (GSK) to reconsider a ruling rejecting its preemption arguments after finding that the company's newly submitted evidence missed the mark as to whether the Food and Drug Administration was aware of an increased risk of suicide in pediatric and adolescent patients using Paxil, but certified the decision for review by the Third Circuit U.S. Court of Appeals (Marion L. Knipe, et al. v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 06-3024, E.D. Pa.; 2008 U.S. Dist. LEXIS 87448; See September 2008, Page 13). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=2-2 Mealey's Diabetes Drug Report 11 (2008)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
</channel>

</rss> 

